Ankylosing Spondylitis

Most patients have predominantly axial involvement (called axial ankylosing spondylitis). Some have predominately peripheral involvement. Among those with axial involvement, some have no evidence of sacroiliitis on plain x-rays. Thus, some experts have classified ankylosing spondylitis as follows:

The most frequent manifestation of ankylosing spondylitis is inflammatory back pain, but disease can begin in peripheral joints, especially in children and women, and rarely with acute iridocyclitis (iritis, anterior uveitis). Other early symptoms and signs are diminished chest expansion from diffuse costovertebral involvement, and occasionally fatigue, anorexia, weight loss, and anemia.

Back pain—often nocturnal and of varying intensity—eventually becomes recurrent. Morning stiffness, typically relieved by activity, and paraspinal muscle spasm develop. A flexed or bent-over posture eases back pain and paraspinal muscle spasm; thus, kyphosis is common in untreated patients. Severe hip and shoulder arthritis can eventually develop and usually has a poor prognosis. In late stages, the patient has accentuated kyphosis, loss of lumbar lordosis, and fixed bent-forward posturing, with compromised pulmonary function and inability to lie flat. There may be peripheral potentially deforming joint involvement, sometimes involving isolated digits diffusely (dactylitis). Achilles and patellar tendinitis can occur.

Systemic manifestations of ankylosing spondylitis occur in one third of patients. Recurrent, acute anterior uveitis is common and usually responds to local therapy; less commonly it becomes protracted and severe enough to impair vision. Neurologic signs occasionally result from compression radiculitis or sciatica, vertebral fracture or subluxation, or cauda equina syndrome. Cardiovascular manifestations can include aortic insufficiency, aortitis, angina, pericarditis, and cardiac conduction abnormalities (which may be asymptomatic). Dyspnea, cough, or hemoptysis can rarely result from nontuberculous fibrosis or cavitation of an upper lobe of the lung; cavitary lesions can become secondarily infected with Aspergillus. Nonspecific colitis has been noted in 30% of patients with ankylosing spondylitis. Subcutaneous nodules, like those in patients with rheumatoid arthritis, do not develop in patients with ankylosing spondylitis.

Ankylosing spondylitis should be suspected in patients, particularly young men, with nocturnal back pain plus prolonged morning stiffness and kyphosis, diminished chest expansion, Achilles or patellar tendinitis, or unexplained anterior uveitis Overview of Uveitis Uveitis is defined as inflammation of the uveal tract—the iris, ciliary body, and choroid. However, the retina and fluid within the anterior chamber and vitreous are often involved as well.... read more . A 1st-degree relative with ankylosing spondylitis should raise suspicion.

Patients should generally be tested with erythrocyte sedimentation rate, C-reactive protein, and complete blood count. Rheumatoid factor (RF) and antinuclear antibodies are needed only if peripheral arthritis suggests other diagnoses. The HLA-B27 allele is present in 90% of White patients with ankylosing spondylitis, but it is also present in up to 10% of the general population depending on ethnicity. No laboratory test is diagnostic, but results can increase suspicion for the disorder or rule out other disorders that can simulate ankylosing spondylitis. If, after these tests, ankylosing spondylitis is still suspected, patients should undergo x-ray or MRI of the lumbosacral spine and sacroiliac joints; demonstration of sacroiliitis on x-ray strongly supports the diagnosis.

Some patients should undergo pelvic MRI to look for sacroiliitis that is not seen on x-rays. In these patients, MRI shows osteitis or early erosions.

Although there are several existing diagnostic criteria for patients with suspected ankylosing spondylitis, the Assessment of SpondyloArthritis international Society (ASAS) criteria (1 Diagnosis references Ankylosing spondylitis is the prototypical spondyloarthropathy and a systemic disorder characterized by inflammation of the axial skeleton, large peripheral joints, and digits; nocturnal back... read more , 2 Diagnosis references Ankylosing spondylitis is the prototypical spondyloarthropathy and a systemic disorder characterized by inflammation of the axial skeleton, large peripheral joints, and digits; nocturnal back... read more , 3 Diagnosis references Ankylosing spondylitis is the prototypical spondyloarthropathy and a systemic disorder characterized by inflammation of the axial skeleton, large peripheral joints, and digits; nocturnal back... read more ) are most often applied. They are useful in diagnosing patients earlier in the disease process, particularly those without spondyloarthritis on imaging. The ASAS criteria for axial spondyloarthritis are applied to patients who have had back pain for > 3 months and who are < 45 years of age at onset.

Diagnosis can be done using ASAS imaging or clinical criteria. To fulfill the imaging criteria, patients must have radiographic or MRI evidence of sacroiliitis plus at least 1 spondyloarthritis feature. To fulfill the clinical criteria, patients must have HLA-B27 plus at least 2 separate spondyloarthritis features. ASAS spondyloarthritis features include the following:

Historical features that distinguish inflammatory back pain from noninflammatory back pain include onset at ≤ 40 years, gradual onset, morning stiffness, improvement with activity, and duration ≥ 3 months before seeking medical attention.

Erythrocyte sedimentation rate and other acute-phase reactants (eg, C-reactive protein) are inconsistently elevated in patients with active ankylosing spondylitis. Tests for RF and antinuclear antibodies are negative. The HLA-B27 genetic marker is minimally helpful because positive and negative predictive values are low.

The earliest x-ray abnormalities are pseudo-widening caused by subchondral erosions, followed by sclerosis or later narrowing and eventually fusion in the sacroiliac joints. Changes are symmetric. Early changes in the spine are upper lumbar vertebral squaring with sclerosis at the corners (shiny corner sign), spotty ligamentous calcification, and one or two evolving syndesmophytes. Late changes result in a “bamboo spine” appearance, resulting from prominent syndesmophytes, diffuse paraspinal ligamentous calcification, and osteoporosis; these changes develop in some patients on average over 10 years.

Changes typical of ankylosing spondylitis may not become visible on plain x-rays for years. MRI shows changes earlier, but there is no consensus regarding its role in routine diagnosis given the lack of prospective, validated data in regard to its diagnostic utility. Pelvic MRI should be done if the index of suspicion of spondyloarthritis is high or if there is a need to rule out other causes of the patient's symptoms. MRI shows early inflammatory changes, bone marrow edema on T2-weighted images with fatty changes, and subtle structural abnormalities. Lastly, routine monitoring of radiographic changes with serial spine x-rays is not recommended.

Ankylosing spondylitis is characterized by mild or moderate flares of active inflammation alternating with periods of little or no inflammation. Proper treatment in most patients results in minimal or no disability and in a full, productive life despite back stiffness. Occasionally, the course is severe and progressive, resulting in pronounced incapacitating deformities.

Poor prognostic factors include persistently high erythrocyte sedimentation rate and C-reactive protein, hip involvement, poor response to NSAIDs, presence of anterior uveitis, or heart or pulmonary disease.

The goals of treatment of ankylosing spondylitis are relieving pain, maintaining joint range of motion, and preventing end-organ damage. Because the condition may cause lung fibrosis, cigarette smoking is discouraged. (See also 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.)

NSAIDs Nonopioid Analgesics Nonopioid and opioid analgesics are the main drugs used to treat pain. Antidepressants, antiseizure drugs, and other central nervous system (CNS)–active drugs may also be used for chronic or... read more reduce pain and suppress joint inflammation and muscle spasm, thereby increasing range of motion, which facilitates exercise and prevents contractures. Most NSAIDs work in ankylosing spondylitis, and tolerance and toxicity dictate drug choice. The daily dose of NSAIDs should be as low as possible, but maximum doses may be needed with active disease. Drug withdrawal should be attempted only slowly, after systemic and joint signs of active disease have been suppressed for several months.

Sulfasalazine may help reduce peripheral joint symptoms and laboratory markers of inflammation in some patients. Dosage should be started at 500 mg/day and increased by 500 mg/day at 1-week intervals to 1 to 1.5 g 2 times a day maintenance; because acute neutropenia can occur, cell counts must be monitored when initiating therapy or increasing drug dose. Peripheral joint symptoms may also abate with methotrexate, but spinal symptoms are usually not reduced. Clinical studies have provided inconsistent results regarding efficacy of these medications.

TNF-alpha antagonists (eg, etanercept, infliximab, adalimumab, certolizumab, golimumab) are often strikingly effective treatments for inflammatory back pain. Adalimumab or infliximab are preferred over etanercept for the treatment of ankylosing spondylitis in patients with recurrent uveitis. For patients who fail TNF-alpha antagonists, switching to an IL-17 antagonist is preferred to switching to another TNF-alpha antagonist.

Secukinumab, an IL-17 antagonist, has also been effective in reducing inflammation and joint symptoms. Secukinumab can be given at a dosage of 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without the loading (weekly) doses, secukinumab is 150 mg subcutaneously every 4 weeks. Adverse effects include urticaria, upper respiratory infections, fungal infections due to Candida, diarrhea, herpes zoster, and worsening symptoms of inflammatory bowel disease.

Ixekizumab, another IL-17 inhibitor, can be given for active ankylosing spondylitis as an injection of 80 mg/mL for adult patients every 4 weeks after a loading dose of 160 mg (two 80-mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12. It can be administered as monotherapy or in combination with conventional DMARDs or NSAIDs.

Discontinuation of biologics is not recommended due to the likelihood for symptom recurrence.

Systemic corticosteroids, immunosuppressants, and most disease-modifying antirheumatic drugs (DMARDs) have no proven benefit in axial spondyloarthritides and should generally not be used.

For proper posture and joint motion, daily exercise and other supportive measures (eg, postural training, therapeutic exercise) are vital to strengthen muscle groups that oppose the direction of potential deformities (ie, the extensor rather than flexor muscles). Reading while lying prone and pushing up on the elbows or pillows and thus extending the back may help keep the back flexible. Because chest wall motion can be restricted, which impairs lung function, cigarette smoking, which also impairs lung function, is strongly discouraged.

Intra-articular depot corticosteroids may be beneficial, particularly when one or two peripheral joints are more severely inflamed than others, thereby compromising exercise and rehabilitation. They may also help if systemic drugs are ineffective. Imaging-guided corticosteroid injections into the sacroiliac joints may occasionally help severe sacroiliitis.

For acute uveitis Overview of Uveitis Uveitis is defined as inflammation of the uveal tract—the iris, ciliary body, and choroid. However, the retina and fluid within the anterior chamber and vitreous are often involved as well.... read more , topical corticosteroids and mydriatics are usually adequate.

If severe hip arthritis develops, total hip arthroplasty may lessen pain and improve flexibility dramatically.

The following English-language resource may be useful. Please note that THE MANUAL is not responsible for the content of this resource.